What Is Compulsory Licensing?

Compulsory licensing is a legal tool that lets governments authorize someone else to make or use a patented product - like a life-saving drug - without the patent holder’s permission. This isn’t about stealing intellectual property. It’s about balancing the rights of companies with the urgent needs of people. The patent holder still gets paid, but the government steps in when the patent is blocking access to something critical - like medicine during a pandemic or a cancer drug that’s priced out of reach.

The idea isn’t new. It dates back to the 1883 Paris Convention, but it became a global standard with the TRIPS Agreement a 1994 international treaty under the World Trade Organization that sets minimum standards for intellectual property protection. Under TRIPS Article 31, countries can issue compulsory licenses if they pay fair compensation and use the product mostly for their own population. The key phrase? "Adequate remuneration." Not a windfall. Not a pittance. Just enough to reflect the value of the invention.

Why Does It Exist?

Patents are meant to encourage innovation. But they can also create monopolies. When a company holds a patent on a drug that costs $1,200 a year - and 10 million people need it - the system breaks. Compulsory licensing exists to fix that. It’s not a weapon. It’s a safety valve.

Take HIV treatment. Between 2000 and 2020, compulsory licenses helped slash the price of first-line HIV medications by 92% in low- and middle-income countries. In Thailand, the government issued licenses for drugs like lopinavir/ritonavir. The price dropped from $1,200 per patient per year to $230. In Brazil, efavirenz went from $1.55 per tablet to $0.48. These weren’t random acts. They were calculated responses to public health emergencies.

The same thing happened during COVID-19. Over 40 countries - including Canada, Germany, and Israel - prepared or issued compulsory licenses for vaccines, tests, and treatments. The goal? Get supplies out fast. No waiting for negotiations. No corporate delays. When lives are on the line, the law allows governments to act.

How It Works in Different Countries

Not all countries use compulsory licensing the same way. The U.S. has the rules, but rarely uses them. There are three main paths:

• Section 1498 - lets the federal government use a patent without permission, but you sue for compensation in the Court of Federal Claims. Between 1945 and 2020, only 10 licenses were issued - all for military or government use.
• Bayh-Dole "march-in" rights - if a company got federal funding to develop a drug and isn’t making it available, the government can force a license. The NIH has received 12 petitions since 1980. It has denied every single one, saying the company "took effective steps."
• Environmental laws - the Clean Air Act allows compulsory licensing if a patented tech is needed to meet pollution standards. Very rare.

Compare that to India. Since 2005, India has issued 22 compulsory licenses - almost all for cancer drugs. In 2012, it licensed Natco Pharma to make a generic version of Bayer’s Nexavar. The price dropped from $5,500 per patient per year to $175. Bayer sued. It took eight years. India won. The ruling set a global precedent: affordability matters more than profit margins when people die waiting.

Thailand, Brazil, South Africa, and Indonesia have all used it. Germany and the UK have the legal tools, but have never issued one. Spain, however, passed emergency rules in 2020 that let them bypass negotiations during the pandemic. The difference? Political will.

The Legal Hurdles

Compulsory licensing isn’t easy. TRIPS says you must try to negotiate with the patent holder first. That’s the "reasonable efforts" rule. But there’s an exception: "circumstances of extreme urgency." That’s what lets countries skip negotiation during a pandemic.

But even when the law allows it, the process is slow. In the U.S., a Section 1498 case takes an average of 2.7 years. In India, the Intellectual Property Appellate Board takes 18 to 24 months. And compensation? It’s messy. The U.S. uses the "Georgia-Pacific factors" - 15 different metrics to calculate what’s "fair." India uses a flat 6% of net sales. No one agrees on the right number.

There’s also the export problem. Before 2005, countries without drug factories couldn’t import generics made under license. The WTO fixed that with a 2003 waiver - later made permanent in 2005. Canada was the only country to use it, shipping HIV drugs to Rwanda in 2012. It’s technically possible. But no one else has tried.

Who Benefits? Who Loses?

Generic drugmakers win. Teva Pharmaceutical made $3.2 billion more between 2015 and 2020 from compulsory license markets. Patients win. In countries with active licensing, drug prices drop 65% to 90%. Governments win. They can control costs and ensure access.

But the pharmaceutical industry says it’s a threat. The IFPMA claims each compulsory license announcement causes an 8.2% drop in stock prices. A 2018 study in the Journal of Health Economics found countries with active licensing saw 15-20% less R&D investment. The fear? If companies can’t protect their profits, they won’t develop new drugs.

But here’s the twist: the threat of compulsory licensing often works better than the license itself. Dr. Brook Baker points out that 90% of HIV drugs in developing countries got price cuts just because manufacturers feared governments would issue licenses. The same thing happened with Hepatitis C drugs. Companies lowered prices preemptively. That’s the real power - not the license, but the possibility of one.

What’s Changing Now?

Things are shifting fast. In June 2022, the WTO agreed to a temporary waiver for COVID-19 vaccine patents. It lets developing countries produce vaccines without permission until 2027. So far, only 12 facilities in 8 countries are using it. Why? Because the paperwork is still too complex. No one’s ready.

The European Union is pushing a new Pharmaceutical Strategy. By 2024, companies may be forced to respond to licensing requests within 30 days - or lose their patent rights. That’s a game-changer. No more dragging your feet.

And the WHO is drafting a Pandemic Treaty. Draft Article 12 says: during a declared global health emergency, essential health products should be automatically licensed. No negotiations. No delays. Just access.

Experts predict that by 2030, 75% of compulsory licenses will be limited to emergencies - cancer, antibiotics, climate-related health tech. Not general use. Not fishing for cheaper drugs. Just when it truly matters.

The Bigger Picture

Compulsory licensing isn’t about undermining innovation. It’s about making sure innovation doesn’t come at the cost of human life. The patent system works when it serves people. When it doesn’t, the law gives governments a way to fix it.

It’s not a first resort. It’s a last one. And that’s how it should be. No one wants to break a patent. But no one should let someone die because a company won’t lower the price.